• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

0.002%异丙基奥米地帕格和0.4%利帕舒地尔诱导的结膜充血程度的模式及相关性评估。

Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4.

作者信息

Terao Etsuko, Nakakura Shunsuke, Nagata Yuki, Dote Saki, Tabuchi Hitoshi, Kiuchi Yoshiaki

机构信息

Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, JPN.

Ophthalmology, Hiroshima University, Hiroshima, JPN.

出版信息

Cureus. 2020 Sep 10;12(9):e10368. doi: 10.7759/cureus.10368.

DOI:10.7759/cureus.10368
PMID:33062491
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7549872/
Abstract

PURPOSE

To evaluate the pattern of conjunctival hyperemia induced by omidenepag isopropyl 0.002% and ripasudil 0.4%, and its correlation with the degree of hyperemia.

SUBJECTS AND METHODS

We previously reported the time course of conjunctival hyperemia induced by administering one drop of omidenepag isopropyl to one eye and one drop of ripasudil to the other eye in 34 healthy subjects (mean age: 29.7 years; 22 females, 12 males). We assessed the degree of hyperemia by slit-lamp photography of the frontal and temporal conjunctiva 0, 15, 30, 60, 120, 180, and 360 min after the administration of one drop of omidenepag isopropyl and ripasudil. The data were used to compare the frontal photographs before and at the peak of hyperemia according to the clinical hyperemia score (0-3) and classify the pattern of developing hyperemia due to both drugs. We also examined the correlation between the degree of hyperemia by comparing the images captured at the peak of hyperemia in both groups, using clinical hyperemia score and "percent coverage" of conjunctival hyperemia by using an automated hyperemia analysis software program; this program provides the pixel coverage of the conjunctival vessels in the region of interest.  Results: There were significant differences in the developmental pattern of hyperemia between omidenepag isopropyl-administered and ripasudil-administered eyes (P<0.001, χ test), with dilation of large blood vessels only (N=2 vs. 1, respectively), small blood vessels only (N=17 vs. 5), both large and small blood vessels (N=8 vs. 27), and no change (N=6 vs. 0). The degree of hyperemia between the two groups was positively correlated with the hyperemia score (rs=0.344, P=0.055) in the frontal conjunctival photographs and the percent coverage of conjunctival blood vessels (r=0.510, P=0.003) in the temporal conjunctival photographs.

CONCLUSIONS

The pattern of conjunctival hyperemia induced by omidenepag isopropyl predominantly involved small blood vessels, whereas that of ripasudil involved both large and small blood vessels. The eyes that were hyperemic with omidenepag isopropyl also tended to be hyperemic with ripasudil.

摘要

目的

评估0.002%异丙基奥米地帕格和0.4%瑞巴派特诱导的结膜充血模式及其与充血程度的相关性。

受试者和方法

我们之前报道了34名健康受试者(平均年龄:29.7岁;女性22名,男性12名)单眼滴入一滴异丙基奥米地帕格,另一只眼滴入一滴瑞巴派特后结膜充血的时间进程。我们在滴入一滴异丙基奥米地帕格和瑞巴派特后的0、15、30、60、120、180和360分钟,通过裂隙灯拍摄额侧和颞侧结膜来评估充血程度。根据临床充血评分(0 - 3分),比较充血高峰时与充血前的额侧照片数据,并对两种药物引起的充血发展模式进行分类。我们还通过比较两组充血高峰时拍摄的图像,使用临床充血评分和自动充血分析软件程序计算结膜充血的“覆盖百分比”来检查充血程度之间的相关性;该程序提供感兴趣区域内结膜血管的像素覆盖情况。结果:异丙基奥米地帕格组和瑞巴派特组的充血发展模式存在显著差异(P<0.001,χ检验),仅大血管扩张(分别为N = 2对1)、仅小血管扩张(N = 17对5)、大小血管均扩张(N = 8对27)以及无变化(N = 6对0)。两组之间的充血程度与额侧结膜照片中的充血评分(rs = 0.344,P = 0.055)以及颞侧结膜照片中结膜血管的覆盖百分比(r = 0.510,P = 0.003)呈正相关。

结论

异丙基奥米地帕格诱导的结膜充血模式主要累及小血管,而瑞巴派特诱导的结膜充血模式则累及大小血管。滴入异丙基奥米地帕格后出现充血的眼睛,滴入瑞巴派特后也往往会出现充血。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e070/7549872/3ecdd713f365/cureus-0012-00000010368-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e070/7549872/d45f4522fbb7/cureus-0012-00000010368-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e070/7549872/4c5a0feff60e/cureus-0012-00000010368-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e070/7549872/3ecdd713f365/cureus-0012-00000010368-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e070/7549872/d45f4522fbb7/cureus-0012-00000010368-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e070/7549872/4c5a0feff60e/cureus-0012-00000010368-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e070/7549872/3ecdd713f365/cureus-0012-00000010368-i03.jpg

相似文献

1
Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4.0.002%异丙基奥米地帕格和0.4%利帕舒地尔诱导的结膜充血程度的模式及相关性评估。
Cureus. 2020 Sep 10;12(9):e10368. doi: 10.7759/cureus.10368.
2
Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4.0.002%奥米德尼帕异丙酯滴眼液引起结膜充血的时间过程:一项与0.4%瑞巴派特对比的探索性研究。
BMJ Open Ophthalmol. 2020 Aug 2;5(1):e000538. doi: 10.1136/bmjophth-2020-000538. eCollection 2020.
3
Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.Rho激酶抑制剂抗青光眼滴眼液(0.4% 利马前列素)诱导结膜充血的时间进程
Curr Eye Res. 2017 May;42(5):738-742. doi: 10.1080/02713683.2016.1250276. Epub 2016 Dec 2.
4
Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial.评价 Rho 激酶抑制剂引起的结膜充血偏移;0.4%利匹司特滴眼液临床试验。
Sci Rep. 2019 Mar 6;9(1):3755. doi: 10.1038/s41598-019-40255-9.
5
Hyperemia Analysis Software for Assessment of Conjunctival Hyperemia Severity.充血分析软件用于评估结膜充血严重程度。
Curr Eye Res. 2019 Apr;44(4):376-380. doi: 10.1080/02713683.2018.1554153. Epub 2018 Dec 12.
6
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.二期、随机、剂量发现研究:Omidenepag Isopropyl,一种选择性 EP2 激动剂,用于原发性开角型青光眼或高眼压症患者。
J Glaucoma. 2019 May;28(5):375-385. doi: 10.1097/IJG.0000000000001221.
7
One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.原发性开角型青光眼患者使用奥美沙坦异丙酯的一年疗效和安全性。
J Ocul Pharmacol Ther. 2022 Jun;38(5):354-358. doi: 10.1089/jop.2021.0122. Epub 2022 May 25.
8
Effects of Brimonidine, Omidenepag Isopropyl, and Ripasudil Ophthalmic Solutions to Protect against HO-Induced Oxidative Stress in Human Trabecular Meshwork Cells.溴莫尼定、奥米德帕格异丙酯和ripasudil滴眼液对人小梁网细胞中HO诱导的氧化应激的保护作用。
Curr Eye Res. 2023 Nov;48(11):1014-1025. doi: 10.1080/02713683.2023.2235892. Epub 2023 Jul 19.
9
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).一项比较原发性开角型青光眼或高眼压症患者每日一次和两次给予地匹福林异丙酯 0.002%的随机 2 期试验(SPECTRUM-6)。
J Glaucoma. 2021 Jun 1;30(6):473-480. doi: 10.1097/IJG.0000000000001836.
10
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.利帕舒地尔-溴莫尼定固定剂量复方与利帕舒地尔或溴莫尼定的药物疗效交叉随机研究。
Adv Ther. 2023 Aug;40(8):3559-3573. doi: 10.1007/s12325-023-02534-w. Epub 2023 Jun 18.

引用本文的文献

1
Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients.近期获批的用于降低和控制眼压以减少高眼压症和青光眼患者视力丧失的药物。
Pharmaceuticals (Basel). 2023 May 26;16(6):791. doi: 10.3390/ph16060791.
2
Topical Medication Therapy for Glaucoma and Ocular Hypertension.青光眼和高眼压症的局部药物治疗
Front Pharmacol. 2021 Dec 1;12:749858. doi: 10.3389/fphar.2021.749858. eCollection 2021.

本文引用的文献

1
Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4.0.002%奥米德尼帕异丙酯滴眼液引起结膜充血的时间过程:一项与0.4%瑞巴派特对比的探索性研究。
BMJ Open Ophthalmol. 2020 Aug 2;5(1):e000538. doi: 10.1136/bmjophth-2020-000538. eCollection 2020.
2
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.奥美地诺前列素异丙酯与拉坦前列素治疗原发性开角型青光眼和高眼压症的疗效比较:AYAME 研究 3 期。
Am J Ophthalmol. 2020 Dec;220:53-63. doi: 10.1016/j.ajo.2020.06.003. Epub 2020 Jun 10.
3
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
二期、随机、剂量发现研究:Omidenepag Isopropyl,一种选择性 EP2 激动剂,用于原发性开角型青光眼或高眼压症患者。
J Glaucoma. 2019 May;28(5):375-385. doi: 10.1097/IJG.0000000000001221.
4
Hyperemia Analysis Software for Assessment of Conjunctival Hyperemia Severity.充血分析软件用于评估结膜充血严重程度。
Curr Eye Res. 2019 Apr;44(4):376-380. doi: 10.1080/02713683.2018.1554153. Epub 2018 Dec 12.
5
Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval.乌米地诺前列素异丙酯滴眼液 0.002%:全球首次获批
Drugs. 2018 Dec;78(18):1925-1929. doi: 10.1007/s40265-018-1016-1.
6
Japanese guidelines for allergic conjunctival diseases 2017.《2017年日本过敏性结膜疾病诊疗指南》
Allergol Int. 2017 Apr;66(2):220-229. doi: 10.1016/j.alit.2016.12.004. Epub 2017 Feb 10.
7
Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.Rho 激酶抑制剂 ripasudil(K-115)联合噻吗洛尔或拉坦前列素的降眼压相加作用:两项随机临床试验报告。
JAMA Ophthalmol. 2015 Jul;133(7):755-61. doi: 10.1001/jamaophthalmol.2015.0525.
8
Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.Rho激酶抑制剂法舒地尔(K-115)对原发性开角型青光眼和高眼压症患者24小时眼压降低作用的随机、开放标签、交叉研究
Acta Ophthalmol. 2015 Jun;93(4):e254-60. doi: 10.1111/aos.12599. Epub 2014 Dec 9.
9
AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.AMA0076,一种新型局部作用的 Rho 激酶抑制剂,可显著降低新西兰白兔的眼内压,且极少引起充血。
Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16. doi: 10.1167/iovs.13-13157.
10
Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.Rho 激酶抑制剂 K-115 治疗原发性开角型青光眼和高眼压症的 2 期随机临床试验
Am J Ophthalmol. 2013 Oct;156(4):731-6. doi: 10.1016/j.ajo.2013.05.016. Epub 2013 Jul 4.